Biodesix, Inc. (BDSX)

Biodesix Expands MRD Testing With Tumor-Informed and Tumor-Naive Tests

Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring

Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings

Biodesix, Inc. (NASDAQ:BDSX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Biodesix to Participate in Upcoming Investor Conferences

What Makes Biodesix, Inc. (BDSX) a Strong Momentum Stock: Buy Now?

Wall Street Analysts See a 26.72% Upside in Biodesix (BDSX): Can the Stock Really Move This High?

PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?

Biodesix Sees Nodify Growth, Reaffirms Revenue Outlook at Canaccord Conference

Biodesix, Inc. (BDSX) Hit a 52 Week High, Can the Run Continue?

Wall Street Analysts Think Biodesix (BDSX) Could Surge 31.91%: Read This Before Placing a Bet

Biodesix, Inc. (BDSX) Q2 2026 Earnings Call Transcript

Biodesix Q2 Earnings Call Highlights

Biodesix, Inc. (BDSX) Reports Q2 Loss, Beats Revenue Estimates

Biodesix Announces Second Quarter 2026 Results and Highlights

Biodesix to Participate in Canaccord Genuity's 46th Annual Growth Conference

BIAF vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?

Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026

Biodesix, Inc. (NASDAQ:BDSX) Receives $28.33 Consensus PT from Brokerages